Novartis Oncology

Novartis Oncology
Share

Novartis Oncology

 •  September 9

Interim results of the head-to-head RIVAL study confirm strong efficacy and comparable durability versus aflibercept in patients with nAMD Five-year results from the Lucentis LUMINOUS study, the largest ever in retinal disease, demonstrate real-world efficacy and safety across five retinal diseases Basel, September 09 2017 - Novartis, the global...

Novartis Oncology

 •  August 30

First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes [1],[2]. Novel approach to cancer treatment is the result of pioneering CAR-T cell therapy collaboration with University of Pennsylvania Reproducible, flexible and validated manufacturing...

Novartis Oncology

 •  August 27

Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is the first Phase III clinical trial to support a long-established hypothesis from pre-clinical models that inhibition of IL-1ß impacts cancer incidence and...

Novartis Oncology

 •  August 27

Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in addition to standard of care including lipid-lowering therapy Effect driven by 24% relative reduction in risk of heart attack; a non-significant 10%...

Novartis Oncology

 •  June 29

In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival (PFS) compared to SOC chemotherapy with maintenance[1] Zykadia benefit was also seen in patients with brain metastases[1] Approximately 3-7% of all patients with NSCLC have an ALK gene rearrangement[2] Basel, June 29, 2017 - Novartis today...

Novartis Oncology

 •  June 23

83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data Data evaluating 63 patients demonstrate relapse-free survival and probability of survival in a majority of patients at six months Advances in CTL019 and ELIANA result from global...

Novartis Oncology

 •  June 7

At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43% achieving CR; full results expected to be available later in 2017 and will serve as basis for US and EU regulatory submissions Global, multi-center Phase...

Novartis Oncology

 •  June 6

Tasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials evaluating TFR with Tasigna in Ph+ CML-CP patients in both the first-line setting and after switching from Glivec® Addition of TFR data to label provides...

Novartis Oncology

 •  June 5

Phase I/II study to evaluate Mekinist® (trametinib) in combination with Opdivo® (nivolumab) and Opdivo + Yervoy® (ipilimumab) Collaboration expands upon existing clinical investigation of Opdivo combination with Novartis investigational and marketed therapies Basel, June 5, 2017 - Novartis today announced it has entered into a clinical research...

Novartis Oncology

 •  April 24

Over 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression; around 58% showed brain shrinkage levels broadly within the range expected for people without MS Approximately 60% of patients achieved NEDA-3 (no relapses, no MRI lesions and no disability progression combined)...